Regeneron Pharmaceuticals (REGN) News Today $813.27 -2.83 (-0.35%) Closing price 04:00 PM EasternExtended Trading$821.25 +7.98 (+0.98%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Regeneron Pharmaceuticals Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Regeneron Extends BARDA Agreement For Additional Ebola Treatment Supply4 hours ago | rttnews.comRegeneron Earnings Preview: Dupixent Is Booming, But It's Still OvervaluedOctober 28 at 8:00 AM | seekingalpha.comWestEnd Advisors LLC Buys 8,528 Shares of Regeneron Pharmaceuticals, Inc. $REGNOctober 28 at 6:31 AM | marketbeat.com20,389 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mcdonald Capital Investors Inc. CAOctober 28 at 6:15 AM | marketbeat.comMissed Regeneron Pharmaceuticals' Rally? Here Is The Bull CaseOctober 27 at 8:46 PM | finance.yahoo.comKiniksa jumps as Q3 results show blockbuster prospects for Regeneron-partnered ArcalystOctober 27 at 3:40 PM | msn.comRegeneron Pharmaceuticals (REGN) Posts Nearly Four Years Of Survival Benefit Data For LibtayoOctober 27 at 4:46 AM | finance.yahoo.comRegeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 EarningsOctober 26 at 9:39 AM | 247wallst.comRegeneron extends US agreement for additional supply of Ebola treatmentOctober 26 at 8:43 AM | msn.comRegeneron Pharmaceuticals Extends Deal to Provide Ebola Treatment to US Government for $270 MillionOctober 26 at 8:43 AM | finance.yahoo.comRegeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. PreparednessOctober 26 at 8:43 AM | finance.yahoo.comRegeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. PreparednessOctober 26 at 7:00 AM | globenewswire.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MAOctober 26 at 6:23 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Stock Holdings Increased by Citizens Financial Group Inc. RIOctober 26 at 4:02 AM | marketbeat.comLibtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)October 25 at 9:03 AM | finance.yahoo.comLibtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)October 25 at 5:15 AM | globenewswire.comEvergreen Capital Management LLC Sells 3,547 Shares of Regeneron Pharmaceuticals, Inc. $REGNOctober 25 at 4:07 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Average Price Target of $846.28 According to AnalystsOctober 25 at 2:15 AM | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (REGN) - What Are Investment Firms Thinking About This Stock?October 25 at 2:13 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Bought by Sterling Capital Management LLCOctober 24, 2026 | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Washington Trust Advisors Inc.October 24, 2026 | marketbeat.comRegeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseOctober 23, 2026 | finance.yahoo.com1 safe-and-steady stock with exciting potential and 2 facing headwindsOctober 23, 2026 | finance.yahoo.comRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, TD Cowen Analyst SaysOctober 23, 2026 | americanbankingnews.comRegeneron Pharmaceuticals (REGN) Projected to Post Quarterly Earnings on FridayOctober 23, 2026 | americanbankingnews.comRegeneron Pharmaceuticals (REGN) Set to Release Quarterly Earnings on FridayOctober 23, 2026 | marketbeat.comRegeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gainsOctober 23, 2026 | marketwatch.comRegeneron: Is The Market Undervaluing Its Growth PotentialOctober 22, 2026 | seekingalpha.comRegeneron Pharmaceuticals, Inc. $REGN Stock Bought by Vest Financial LLCOctober 22, 2026 | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Newly Bought by Cantor Fitzgerald Investment Advisors L.P.October 22, 2026 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from TD CowenOctober 21, 2026 | marketbeat.comRobeco Institutional Asset Management B.V. Sells 57,644 Shares of Regeneron Pharmaceuticals, Inc. $REGNOctober 21, 2026 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Piper Sandler Analyst SaysOctober 21, 2026 | americanbankingnews.comStrong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial ResultsOctober 19, 2026 | finance.yahoo.comStrong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial ResultsOctober 19, 2026 | insidermonkey.comRegeneron Pharmaceuticals, Inc. $REGN Shares Purchased by BDF GestionOctober 19, 2026 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Given New $865.00 Price Target at Piper SandlerOctober 19, 2026 | marketbeat.comForget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss MarketOctober 19, 2026 | fool.comRegeneron's Murphy sells $3.2 million in stock under plan (NASDAQ: REGN)October 19, 2026 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. $REGN Stock Sold by Assenagon Asset Management S.A.October 19, 2026 | marketbeat.com10,570 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Vontobel Holding Ltd.October 18, 2026 | marketbeat.comForget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit ShareOctober 17, 2026 | fool.comRegeneron Pharmaceuticals (NASDAQ:REGN) Raised to Buy at UBS GroupOctober 17, 2026 | americanbankingnews.comRegeneron's Libtayo Wins EMA CHMP Support For Extended DosingOctober 16, 2026 | rttnews.comCHMP Backs Less Frequent Regeneron's Libtayo Dosing Across Approved Cancer Indications In EuropeOctober 16, 2026 | rttnews.comQ2 earnings highlights: Regeneron (NASDAQ: REGN) vs the rest of the biotechnology stocksOctober 16, 2026 | msn.comDid Earnings Beat Just Shift Regeneron Stock Investment Narrative?October 16, 2026 | finance.yahoo.comLibtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer TypesOctober 16, 2026 | globenewswire.com1,651 Shares of Regeneron Pharmaceuticals, Inc. $REGN Purchased by Milestone Asset Management LLCOctober 16, 2026 | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Stock Sold by Curated Wealth Partners LLCOctober 16, 2026 | marketbeat.com Regeneron Pharmaceuticals Media Mentions By Week Regeneron Pharmaceuticals Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REGN News Sentiment▼0.760.69▲Average Healthcare News Sentiment Regeneron Pharmaceuticals News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REGN Articles This Week▼319▲REGN Articles Average Week Regeneron Pharmaceuticals Trends on MarketBeatThis week vs. last weekNew Followers1Searches2Page Views6,645-1% Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Amgen News Gilead Sciences News Moderna News Intellia Therapeutics News Vir Biotechnology News Vertex Pharmaceuticals News AbbVie News Eli Lilly and Company News Merck & Co., Inc. News Pfizer News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Regeneron Pharmaceuticals dated 10/28/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredTrump Goes "All-In" on Grand Canyon Energy BreakthroughOn July 4th, Washington cut tax credits for solar, wind, and EVs, but extended eight years of credits to one e...Behind the Markets | SponsoredNEVER thought this would happen againTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
